Measuring IGF-1 and IGFBP-3 profiles in women seeking assisted reproduction; response of women categorized as poor-prognosis to recombinant growth hormone adjuvant therapy (Study 4)

John L Yovich; Syeda Zaidi; Minh DK Nguyen; Peter M Hinchliffe

doi:10.30574/gscbps.2020.13.3.0358

Authors

John L Yovich PIVET Medical Centre Perth, Western Australia Australia 6007.
Syeda Zaidi Department of Obstetrics and Gynecology, Faculty of Medicine, University of Malaya Lembah Pantai, Kuala Lumpur Malaysia 59100.
Minh DK Nguyen PIVET Medical Centre Perth, Western Australia Australia 6007.
Peter M Hinchliffe PIVET Medical Centre Perth, Western Australia Australia 6007.

DOI:

https://doi.org/10.30574/gscbps.2020.13.3.0358

Keywords:

Human Growth Hormone (hGH), Insulin-Like Growth Factor-1 (IGF-1), Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3), IGF Profile (IGF-1, IGFBP-3 and IGF Ratio), IGFBP-3/ IGF-1 Ratio (IGF Ratio), Assisted Reproductive Technology (ART), In Vitro Fertilization (IVF), Recombinant Growth Hormone (rGH), GH Adjuvant.

Abstract

In this fourth study examining the relevance of measuring the IGF profile (IGF-1, IGFBP-3 and the ratio of IGFBP-3/ IGF-1) in women presenting for assisted reproductive technologies (ART), we have examined the influence of recombinant growth hormone (rGH) prescribed as an adjuvant on the profile. Of 1633 ART-naïve women who completed an assessment cycle (AC) workup, and which included an IGF profile, 941 women proceeded to an in-vitro fertilization ± intracytoplasmic sperm injection (IVF±ICSI) treatment cycle during the period January 2011 to December 2019. Among those women, 90 were prescribed rGH because they were classified as likely poor-prognosis cases on the basis of advanced age or evidence of severely reduced ovarian reserve parameters. These women had their IVF±ICSI treatment within 3-months of their AC and consented to a second IGF profile measurement 4-6 weeks during their rGH treatment phase. Of the 90 women prescribed rGH adjuvant, 71 used the adjuvant and 19 deferred the treatment, but still completed the second IGF-profile. The data showed that rGH caused a significant elevation in IGF-1 (p<0.0001) as well as its main binding protein, IGFBP-3 (p<0.001), albeit to a lesser degree. Consequently, the IGF ratio, considered a more reliable marker of IGF-1 activity, was shown to be significantly reduced towards the normal range (p<0.0001). The data of clinical outcomes from these 90 women as well as the entire 941 women entering the IVF±ICSI treatment are presented for comparison, noting these data are not suitable for statistical evaluation as the groupings are disparate and unmatched. Further studies are intended to show the clinical relevance of increasing the IGF-1 levels in the analytical investigation of rGH as an adjuvant in ART.

Metrics

Metrics Loading ...

References

Annual Capri Workshop Group. IVF, from the past to the future: the inheritance of the Capri Workshop Group. Hum Reprod Open, 2020; pp1-9, doi: 10.1093/hropen/hoaa040

Yovich JL, Stanger JD. Growth hormone supplementation improves implantation and pregnancy productivity rates for poor-prognosis patients undertaking IVF, Reprod Biomed Online, 2010; 21: 37-49: doi: 10.1016/j.rbmo.2010.03.013

Keane KN, Yovich JL, Hamidi A, Hinchliffe PM, Dhaliwal SS. A single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis. BMJ Open, 2017; 7(e018107):1-9, doi: doi:10.1136/bmjopen-2017-018107

Keane KN, Ye Y, regan SLP, Dhaliwal SS, yovich JL. Live birth outcomes of vitrified embryos generated under growth hormone stimulation are improved for women categorized as poor-prognosis. Clin Exp Reprod Med, 2019; 46(40):178-188, doi: 10.5653/cerm.2019.00206

Yovich JL, Ye Y, Regan SLP, Keane KN. The evolving concept of poor-prognosis for women undertaking IVF and the notion of growth hormone as an adjuvant; a single-center viewpoint. Front Endocrinol, 2019; 10:808; pp14, doi.org/10.3389/fendo.2019.0080

Yovich JL, Regan SL, Zaidi SN, Keane KN. The concept of growth hormone deficiency affecting clinical prognosis in IVF. Front Endocrinol, 2019; 10: 650, doi: 10.3389/fendo.2019.00650

Weall BM, Al-Samerria S, Conceicao J, Yovich JL, Almahbobi G. A direct action for GH in improvement of oocyte quality in poor-responder patients. Reproduction, 2015; 149(2):147-154, doi: 10.1530/REP-14-0494

Regan SLP, Knight PG, Yovich JL, Arfuso F, Dharmarajan A. Growth hormone during in vitro fertilization in older women modulates the density of receptors in granulosa cells, with improved pregnancy outcomes. Fertil Steril 2018; 110: 1298–1310.

Yovich JL, Zaidi S, Nguyen MDK, Hinchliffe PM. Measuring IGF-1 and IGFBP-3 profiles in women seeking assisted reproduction; relationship to serum growth hormone levels (Study 3). GSC Biological and Pharmaceutical Sciences, 2020; 13(03), 032-053.

Stanley T. Diagnosis of growth hormone deficiency in childhood. Curr Opin Endocrinol Diabetes Obes, 2012; 19: 47-52, doi: 10.1097/MED. 0b013e32834ec952

Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2011; 96(6):1587–1609, doi: 10.1210/jc.2011-0179

Yovich JL, Zaidi S, Nguyen MDK, Hinchliffe PM. Measuring IGF-1 and IGFBP-3 profiles in women seeking assisted reproduction; relationship to clinical parameters (Study 1). J Pers Med,2020; 10:122 doi: 10.3390/jpm10030122

Yovich JL, Zaidi S, Nguyen MDK, Hinchliffe PM. Measuring IGF-1 and IGFBP-3 profiles in women seeking assisted reproduction; relationship to ovarian reserve parameters (Study 2). GSC Biological and Pharmaceutical Sciences, 2020; 13(02), 035-053.

Yovich J, Stanger J, Hinchliffe P. Targeted gonadotrophin stimulation using the PIVET algorithm markedly reduces the risk of OHSS. Reprod Biomed Online, 2012; 24(3):281-292, doi: 10.1016/j.rbmo.2011.11.014

Yovich JL, Alsbjerg B, Conceicao JL, Hinchliffe PM, Keane KN. PIVET rFSH dosing algorithms for individualized controlled ovarian stimulation enables optimized pregnancy productivity rates and avoidance of ovarian hyperstimulation syndrome. Drug Des Devel Ther, 2016; 10: 2561–573, doi: 10.2147/DDDT.S104104

Yovich JL. How to Prepare the Egg and Embryo to Maximise IVF Success. In: Monitoring the stimulated IVF cycle. Section II: Stimulation for IVF (Eds: Gabor T Kovacs, Anthony J Rutherford, David K Gardner). Cambridge University Press, Cambridge, UK, 2019; 94-120 doi: 10.1017/9781316756744

Yovich JL, Hinchliffe PM, Lingam S, Srinivasan S, Keane KN. Adjusting the PIVET rFSH dosing algorithm for the biosimilar Bemfola product. J Fertil In vitro IVF Worldw Reprod Med Genet Stem Cell Biol, 2018; 5:3, doi: 10.4172/2375-4508.1000207

Yovich JL, Craft IL. Founding pioneers of IVF: Independent innovative researchers generating livebirths within 4 years of the first birth. Reprod Biol, 2018; 18:317-323, doi.org/10.1016/J.repbio.2018.11.004

Yovich JL. Founding pioneers of IVF Update: Independent innovative researchers generating livebirths within 4 years of the first birth. Reprod Biol, 2020; 20:111-113, doi.org/10.1016/j.repbio.2019.12.008

Kuwayama M, Vajta G, Kato O, Leibo SP. Highly efficient vitrification method for cryopreservation of human oocytes. Reprod Biomed Online, 2005; 11:300-308, doi: doi: 10.1016/s1472-6483(10)60837-1

Newman JE, Paul RC, Chambers GM. Assisted reproductive technology in Australia and New Zealand 2018. Sydney: National Perinatal Epidemiology and Statistics Unit, the University of New South Wales, Sydney, 2020; 1-83.

Hammer Ø, Harper DAT, Ryan PD. PAST: Paleontological Statistics software package for education and data analysis. Palaentologia Electronica 2001; 4(1): 9pp

Norman RJ, Alvino H, Hull LM, Mol BW, Hart RJ, Kelly TL, Rombauts L. Human growth hormone for poor responders: a randomized placebo-controlled trial provides no evidence for improved live birth rate. Reprod Biomed Online, 2019; 38:908–915, doi: 10.1016/j.rbmo.2019.02.003

Hull KL, Harvey S. Growth hormone and reproduction: a review of endocrine and autocrine, paracrine interactions. Int J Endocrinol, 2014; Article ID 234014: pp24, doi: 10.1155/2014/234014

Steyn FJ, Tolle V, Chen C, Epelbaum J. Neuroendocrine regulation of growth hormone secretion. Compr Physiol, 2016; 6(2):687-735, doi: 10.1002/cphy.c150002. PMID: 27065166.

Ipsa E, Cruzat VF, Kagize JN, Yovich JL, Keane KN. Growth Hormone and Insulin-like growth factor in reproductive tissues. Front Endocrinol 2019; 777 pp14 doi: 10.3389/fendo.2019.00777

Matsuda F, Inouie N, Manabe N, Okhura S. Follicular growth and atresia in mammalian ovaries: regulation by survival and death of granulosa cells. J Reprod Dev, 2012; 58:44-50, doi: 10.1262/jrd.2011-012

Devesa J, Caicedo D. The role of growth hormone on ovarian functioning and ovarian angiogenesis. Front Endocrinol, 2019; 10:pp16, doi: 10.3389/fendo.2019.00450

Allard JB, Cunming D. IGF-binding proteins: why do they exist and why are there so many? Front Endocrinol, 2018; 9:117, pp12, doi: 10.3389/fendo.2018.0017

Juul A, Main K, Blum WF, LindholmJ, Ranke MB, Skakkebaek NE. The ratio between serum levels of insulin-like growth factor (IGF)-1 and the IGF binding proteins (IGFBP-1,2, and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin endocrinol (oxf), 1994; 41(1):85-93, doi: 10.1111/j.1365-2265.1994.tb03788.x

Gaddas M, Périn L, Le Bouc Y. Evaluation of IGF1/IGFBP3 molar ratio as an effective tool for assessing the safety of growth hormone therapy in small-for-gestational-age, growth hormone-deficient and Prader-Willi children. J Clin Res Pediatr Endocrinol 2019; 11(3): 253-261, doi: 10.4274/jcrpe.galenos.2019.2018.0277

Nasioudis D, Minis E, Irani M, Kreines F, Witkin SS, Spandorfer SD. Insulin-like growth factor-1 and soluble FMS-like tyrosine kinase-1 prospectively predict cancelled IVF cycles. J Assist Reprod Genet, 2019; 36(12):2485-2491, doi: 10.1007/s10815-019-01618-3.

Man L, Lekovich J, Canon C, Rosenwaks Z, James D. 2019. Cycle day-2 insulin-like growth factor-1 serum levels as a prognostic tool to predict controlled ovarian hyperstimulation outcomes in poor responders. Fertil Steril 2020; 113: 1205-1214. Doi.org/10.1016/j.fertnstert.2020.02.111.